UK’s lax regulation fuels a black‑market surge in experimental peptides, exposing systemic gaps in drug oversight and consumer protection
Original framing: “UK becoming ‘wild west’ for experimental peptides, expert warns” — The Guardian - World
Peer‑reviewed pharmacology indicates that many advertised peptides lack reproducible efficacy data and carry unknown immunogenic risks, especially when sourced from unverified supply chains. Robust scientific assessment requires coordinated post‑market surveillance that is currently absent in the UK’s fragmented system.
The UK’s peptide boom is not merely a tale of rogue sellers but a symptom of fragmented drug governance, historic deregulation cycles, and a digital economy that sidesteps public health safeguards.
Indigenous and cross‑cultural traditions illustrate that communal oversight can coexist with scientific rigor, offering a model for hybrid regulatory frameworks. By embedding community‑driven pharmacovigilance, unifying oversight agencies, and enforcing transparent digital standards, the system can pre‑empt the health crises that sensationalist headlines currently warn about. These interventions, grounded in historical precedent and future modelling, must be financed and coordinated by government, industry, and civil society to dismantle the structural drivers of the underground peptide market.